Anti-tumour therapy in paraneoplastic neurological disease.
Paraneoplastic neurological syndromes have attracted attention in recent years. Detection of auto-antibodies directed against CNS and PNS structures have suggested an autoimmune etiology. This review is based on reports from the past 10 years and summarizes the therapeutic results in 258 patients suffering from paraneoplastic neurological disease including paraneoplastic encephalomyelitis, sensory neuronopathy, cerebellar degeneration, motor neurone disease and stiff man syndrome. The results show that in some entities such as Lambert-Eaton syndrome successful treatment can be expected. In other syndromes such as subacute sensory neuronopathy or paraneoplastic cerebellar degeneration therapeutic success varies from 5 to 10%.
Grisold
W
W
Neurological Department, Kaiser Franz Josef Hospital, Vienna, Austria.
Drlicek
M
M
Liszka-Setinek
U
U
Wondrusch
E
E
D000970:Antineoplastic Agents / Q000008:administration & dosage; D001323:Autoantibodies / Q000032:analysis; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy*; D001921:Brain / Q000276:immunology; D003131:Combined Modality Therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D015624:Lambert-Eaton Myasthenic Syndrome / Q000276:immunology / Q000628:therapy; D009422:Nervous System Diseases / Q000276:immunology / Q000628:therapy*; D009460:Neurologic Examination; D010257:Paraneoplastic Syndromes / Q000276:immunology / Q000628:therapy*; D011379:Prognosis
D000970:Antineoplastic Agents; D001323:Autoantibodies; D007166:Immunosuppressive Agents